SEC Form 4 · accession 0001562180-15-000467
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Anderson
Officer — See Remarks
Period of report
Jun 8, 2015
Accepted (ET)
Jun 8, 2015 · 1:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2015 | M | 5,500 | $8.92 | A | 11,500 | D | |
| Common StockF2 | Jun 8, 2015 | S | 4,300 | $79.95 | D | 7,200 | D | |
| Common StockF3 | Jun 8, 2015 | S | 1,200 | $78.56 | D | 6,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F4 | $8.92 | Jun 8, 2015 | M | 5,500 | D | — | May 21, 2024 | Common Stock | 5,500 | 132,169 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $79.15 USD to $80.09 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $78.26 USD to $78.96 USD. The price reported above reflects the weighted average sale price.
- F4The option, representing a right to purchase a total of 137,669 shares, became partially exercisable beginning on May 05, 2015. 25% of this option vested on May 05, 2015 and the remainder vests in equal monthly installments thereafter over 36 months.